GSK Advair Panel Review Will Focus On Single Survival Study
FDA is asking the Pulmonary-Allergy Drugs Advisory Committee whether results of GSK’s sole survival study are robust and what additional data would be needed for a survival claim.
FDA is asking the Pulmonary-Allergy Drugs Advisory Committee whether results of GSK’s sole survival study are robust and what additional data would be needed for a survival claim.